about
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteersEpigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancerLaparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: a systematic reviewNetwork-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer RiskAltretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II studyMolecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortiumGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSA genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.Genome-wide association study identifies a common variant associated with risk of endometrial cancer.Common variants at 19p13 are associated with susceptibility to ovarian cancer.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupBilateral Mammary Tuberculosis Associated with a Borderline Ovarian Tumor.The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluationPhase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.ZD9331 in combination with topotecan: phase I and II experience.Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.Supervised classification of array CGH data with HMM-based feature selection.Incorporation of pazopanib in maintenance therapy of ovarian cancer.Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerPhase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumNeoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancerPolymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS.International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
P50
Q21195201-09329273-F35A-4E91-8D37-8C1864328FB5Q24633316-69F52601-C219-47AA-ABF0-53E1AC5EE453Q26745917-1DE45F9A-CACC-495A-BD5E-F0097642049DQ26799669-30CBFCCD-3DBB-486A-AAA3-F99236B13C00Q28209431-46C95685-FF22-45DE-85EC-DF6D5A491880Q28275893-CEF2FA16-947D-4176-8782-58809F01522AQ28388497-3DBC7A1B-11A9-42A5-A0B7-7A156DBEA18BQ28584533-E00181F0-4E27-4FDF-AD1B-D5FA2EE1B43CQ29417084-13100893-8E58-46FC-8F71-24B4AB13BEE9Q29417135-9B452689-6FAA-4E4B-BD83-7F86C7E9322BQ29417145-2DA96536-28FD-46E5-891B-1796F917DFA3Q30252854-9BD7899E-EE96-42F8-9138-EA8BADB56D2DQ30275832-BAB88DF4-C663-4588-B2C6-83B9C32CD5DAQ30276986-C7A251F4-0EDF-4D5A-B4FC-D1B72401543CQ30374367-91865104-78E2-4AAB-986D-D907F7AFEFC9Q30478027-36B75602-888E-450B-8599-E438DAF211F9Q30479641-0B2B45EF-4D54-458A-97E7-25AB3929ED66Q33202606-0A46F4BB-A663-47BC-95E0-CBCBEE6BAC9FQ33315705-6696035D-CF92-4982-8D33-A9F9AA500017Q33347078-783EE448-418C-4178-A7EB-059FA3708FA1Q33357232-65FC87AF-6007-41F3-9674-3EA557D9AFDFQ33364185-24D6A513-DA0E-466D-BB3D-59B988DBBF6BQ33408232-8AD3551E-706E-4967-A66D-520974B2FF20Q33417673-830D7630-A8F8-46E9-9991-DA8C9ABD13C2Q33419460-FDC5748D-C83D-47A4-B5F5-979FBCBA227AQ33422082-C3039FB8-5695-4C1D-B63F-A67D6B754F8FQ33423436-0925ED20-A908-4D0C-8B85-DFED2938E203Q33427744-66B5A498-B318-4AB6-81DF-4153B1370242Q33435836-8A15BB80-0ADC-4C92-B48A-6ACE0350322AQ33438805-52E83F2F-625C-4B89-B019-F966A19C7961Q33624809-660F26EE-9EFD-4BB9-A044-2F2BA66FF9B7Q33626973-73286AA1-D261-408A-9694-16E79F339731Q33750749-1123A2F2-617A-444F-9192-68CF88BCA9CFQ33778612-DCFF6711-7344-4702-A68D-C444A7DB2747Q33827681-62E23063-6F7A-4CBD-9C5F-461643B492DDQ33847791-56C457E7-B398-4CFF-8714-DEA47EB806E8Q33921008-124223F3-D035-48F7-92B4-109D8D2FDCF8Q33947899-40586DD5-DDCD-47A8-8B31-A604D60EBE89Q33961876-118E7BA1-D613-45BA-A1CC-C69CFD9FFC8DQ33963742-BCE304A8-913D-4474-A6CA-8A5785614006
P50
description
researcher
@en
name
Ignace Vergote
@en
type
label
Ignace Vergote
@en
prefLabel
Ignace Vergote
@en
P31
P496
0000-0002-7589-8981